Compare AbbVie Inc (ABBV) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Uber Technologies Inc — how do they compare? AbbVie Inc trades at $253.03 (market cap $449.91B), while Uber Technologies Inc trades at $73.21 (market cap $151.31B). The key difference: AbbVie Inc is far larger — about 3× Uber Technologies Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | UBER | |
|---|---|---|
Market Cap | $449.91B | $151.31B |
Sector | Health | Industrials |
52-Week High | $261.07 | $100.10 |
52-Week Low | $184.85 | $68.61 |
Enterprise Value | $513.38B | $157.63B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Uber (UBER) trades at $72.42, down 2.7% today, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $52.02 billion, and a net income margin of 15.91%. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, while cost-cutting measures like HR layoffs aim to improve efficiency.
The outlook is mixed: analyst consensus is strongly bullish with a $109.25 price target, but technical indicators and projected 2026 cash flow decline pose risks. Key opportunities include expansion in autonomous driving partnerships; risks involve competitive pressures and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
